Trivia Answer, Posted -- And Likely Mooted, Too

The lasting importance of the answer to yesterday's trivia question was likely diminished by today's events, but yes, this is where the language may be found: in a suit to enjoin the Pfizer-Wyeth merger, on antitrust claims, in the federal District Court, for the Northern District of California, captioned Golden Gate Pharmacy, et al. v. Pfizer, et al. (Case No. 09-3854):

. . . .More recently, Merck’s intended acquisition of Schering-Plough will even further concentrate the relevant markets, including the pharmaceutical innovation markets. (Id. ¶ 22.) In 2008, Merck spent $4.8 billion on research and development, and Schering-Plough spent $3.5 billion, for a total of $8.3 billion. The Merck-Schering-Plough merger will therefore account for 22 per cent of pharmaceutical industry domestic spending on research and development and 17 per cent world-wide. . . .